Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients (Englisch)
- Neue Suche nach: Chen, Peng
- Neue Suche nach: Chen, Fuchao
- Neue Suche nach: Chen, Peng
- Neue Suche nach: Chen, Fuchao
In:
Alimentary Pharmacology & Therapeutics
;
57
, 11
;
1349-1350
;
2023
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients
-
Beteiligte:Chen, Peng ( Autor:in ) / Chen, Fuchao ( Autor:in )
-
Erschienen in:Alimentary Pharmacology & Therapeutics ; 57, 11 ; 1349-1350
-
Verlag:
-
Erscheinungsdatum:01.06.2023
-
Format / Umfang:2 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Datenquelle:
Inhaltsverzeichnis – Band 57, Ausgabe 11
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1213
-
Issue Information| 2023
- 1216
-
Review article: Putting some muscle into sarcopenia—the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel diseaseGold, Stephanie L. / Raman, Maitreyi / Sands, Bruce E. / Ungaro, Ryan / Sabino, João et al. | 2023
- 1231
-
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugsOlivera, Pablo A. / Lasa, Juan S. / Peretto, Giovanni / Zuily, Stephane / Danese, Silvio / Peyrin‐Biroulet, Laurent et al. | 2023
- 1249
-
Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot studyIkegami, Shuji / Nakamura, Masanao / Honda, Takashi / Yamamura, Takeshi / Maeda, Keiko / Sawada, Tsunaki / Ishikawa, Eri / Yamamoto, Kenta / Furune, Satoshi / Ishikawa, Takuya et al. | 2023
- 1258
-
Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trialGunn, David / Topan, Rabia / Barnard, Lorna / Fried, Ron / Holloway, Ivana / Brindle, Richard / Corsetti, Maura / Scott, Mark / Farmer, Adam / Kapur, Kapil et al. | 2023
- 1272
-
Buspirone for early satiety and symptoms of gastroparesis: A multi‐centre, randomised, placebo‐controlled, double‐masked trial (BESST)Parkman, Henry P. / Yates, Katherine P. / Sarosiek, Irene / Bulat, Robert S. / Abell, Thomas L. / Koch, Kenneth L. / Kuo, Braden / Grover, Madhusudan / Farrugia, Gianrico / Silver, Paul et al. | 2023
- 1290
-
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective studyFumery, Mathurin / Nancey, Stéphane / Filippi, Jérôme / Altwegg, Romain / Hébuterne, Xavier / Boshetti, Gilles / Barraud, Mathilde / Meynier, Jonathan / Paul, Stéphane / Roblin, Xavier et al. | 2023
- 1299
-
Entecavir versus tenofovir on prognosis of hepatitis B virus‐related hepatocellular carcinoma after curative hepatectomyKao, Wei‐Yu / Tan, Elise Chia‐Hui / Lee, Hsin‐Lun / Huang, Yi‐Hsiang / Huo, Teh‐Ia / Chang, Chun‐Chao / Chiou, Jeng‐Fong / Hou, Ming‐Chih / Wu, Jaw‐Ching / Su, Chien‐Wei et al. | 2023
- 1313
-
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohortJost‐Brinkmann, Fabian / Demir, Münevver / Wree, Alexander / Luedde, Tom / Loosen, Sven H. / Müller, Tobias / Tacke, Frank / Roderburg, Christoph / Mohr, Raphael et al. | 2023
- 1326
-
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel diseaseCaldera, Freddy / Spaulding, Aaron C. / Borah, Bijan / Moriarty, Jim / Zhu, Ye / Hayney, Mary S. / Farraye, Francis A. et al. | 2023
- 1335
-
Editorial: ondansetron for patients with IBS‐D and bowel‐predominant symptomsShah, Eric D. et al. | 2023
- 1337
-
Editorial: ondansetron for patients with IBS‐D and bowel‐predominant symptoms—authors' replyGunn, David / Ford, Alexander / Farrin, Amanda / Spiller, Robin et al. | 2023
- 1339
-
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet?Tye‐Din, Jason A. et al. | 2023
- 1341
-
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' replyGarzón‐Benavides, Marta / Rodríguez‐Herrera, Alfonso / Sousa, Carolina / Pizarro‐Moreno, Angeles et al. | 2023
- 1343
-
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease—time for universal recommendation?Macaluso, Fabio Salvatore / Orlando, Ambrogio et al. | 2023
- 1345
-
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease—time for universal recommendation? Authors' replyCaldera, Freddy / Spaulding, Aaron C. / Hayney, Mary S. / Farraye, Francis A. et al. | 2023
- 1347
-
Editorial: buspirone for gastroparesis—an intriguing option for a challenging conditionSayuk, Gregory S. et al. | 2023
- 1349
-
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patientsChen, Peng / Chen, Fuchao et al. | 2023
- 1351
-
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ replyIkegami, Shuji / Nakamura, Masanao / Honda, Takashi / Kawashima, Hiroki et al. | 2023
- 1353
-
Letter: eosinophilic duodenitis and increased intraepithelial lymphocytes in rumination syndrome – more evidenceZand Irani, Mudar / Eslick, Guy D. / Brown, Georgia / Talley, Nicholas J. et al. | 2023
- 1355
-
Letter: factors influencing discontinuation of aspirin in patients after gastrointestinal bleedingZhao, Jian / Huang, Kun / Hu, Bowen et al. | 2023
- 1357
-
Letter: factors influencing discontinuation of aspirin in patients after gastrointestinal bleeding – authors' replyLi, Darrick K. / Laine, Loren et al. | 2023
- 1358
-
Letter: pre‐emptive TIPSS and the risks of uncertaintyBerry, Philip / Kotha, Sreelakshmi et al. | 2023